<div id="readability-page-1" class="page"><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Sinopharm Group Co ( (HK:1099) ) has issued an update. Sinopharm Group has disclosed the 2025 audited financial results of its Shanghai-listed subsidiary China National Medicines Corporation, showing modest top-line growth but largely flat profitability. Revenue rose 3.7% year on year to RMB 52.47 billion, while net profit attributable to shareholders slipped 0.18% to RMB 1.997 billion, and earnings per share were essentially unchanged. Despite the slight earnings decline, SINOPHARM CNCM improved its cash generation, with net operating cash flow up 20.88% versus 2024 and net assets attributable to shareholders increasing 8.27%. The weighted average return on net assets fell by nearly one percentage point, indicating some margin pressure even as total assets expanded 5.03%, suggesting steady but moderating profitability for stakeholders in a growing asset base. The most recent analyst rating on (HK:1099) stock is a Buy with a HK$23.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page. More about Sinopharm Group Co Sinopharm Group Co. is a major Chinese pharmaceutical and healthcare company, with its subsidiary China National Medicines Corporation Ltd. (SINOPHARM CNCM) engaged in the distribution and trade of medicines and related healthcare products. The subsidiary’s A shares are listed on the Shanghai Stock Exchange, positioning it as a significant player in China’s pharmaceutical supply chain. Average Trading Volume: 5,305,954 Technical Sentiment Signal: Strong Buy Current Market Cap: HK$65.72B For an in-depth examination of 1099 stock, go to TipRanks’ Overview page.</div>

000028

600056

600511

Sinopharm Group Co. has reported its 2025 financial results for its subsidiary, China National Medicines Corporation. Revenue increased by 3.7% to RMB 52.47 billion, while net profit fell slightly by 0.18% to RMB 1.997 billion, with earnings per share remaining stable. The subsidiary improved cash flow, with net operating cash flow rising by 20.88%. Despite a decline in return on net assets, total assets grew by 5.03%. Analysts rate the stock as a Buy with a target price of HK$23.00.

Tip Ranks

Sinopharm Accord

China Meheco

SINOPHARM(CNCM LTD)

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

China Universal 800 Health Care ETF

Guotai CSI Bio-medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Sinopharm Subsidiary Posts 2025 Revenue Growth Amid Flat Earnings and Stronger Cash Flow